Y-mAbs Therapeutics New Drug Application Gets FDA Clearance
By Denny Jacob
Y-mAbs Therapeutics' investigational new drug application for CD38-SADA was cleared by the Food and Drug Administration.
The commercial-stage biopharmaceutical company said CD38-SADA is its second program within its self-assembly disassembly pre-target radioimmunotherapy theranostic platform. The Phase 1 trial is investigating the safety and tolerability of the CD38-SADA: (177) Lu-DOTA Drug Complex in patients with relapsed or refractory non-Hodgkin lymphoma.
Interim Chief Executive Thomas Gad said the FDA's clearance marks the second program utilizing its SADA technology platform to enter clinic development within just 15 months.
Y-mAbs said it expects to dose the first patient in its Phase 1 trial in 2024.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
October 17, 2023 17:46 ET (21:46 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
New 4-Star Stocks
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage